Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016

Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, discusses the latest updates in T cell lymphomas that is being presented at ASH 2016

Published: 14 December 2016

Recent Videos: Lymphoma (includes NHL, HL, CNS Lymphoma)

video

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

Dr. Kahl elaborates on the evidence for using rituximab maintenance as a front-line treatment option with bendamustine-rituxan in follicular lymphoma ...

video

Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL

Dr. Kahl elaborates on his study evaluating ADCT-402 in diffuse large B-cell lymphoma (DLBCL)

video

Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma

Dr. Kahl shares information on the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma presented at ASH 2017

video

Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma

Dr. Kahl offers his opinion on the unmet needs in Hodgkin lymphoma

video

John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL

Dr. Burke, on whether rituximab is an effective maintenance strategy after 1st line bendamustine-rituximab in previously untreated follicular lymphoma patients

video

Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma

Dr. Copelan elaborates on how allogeneic transplantation is being optimized for lymphoma and myeloma patients and how it compares with ...

video

Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017

Dr. Rule tells us about the presentation of the ibrutinib data in relapsed/refractory mantle cell lymphoma (MCL) presented at ASH ...

video

Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)

Dr. Rule shares his thoughts on the clinical development plan with Imbruvica (ibrutinib) in mantle cell lymphoma (MCL)

video

Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies

Dr. Hagemeister shares what physicians should know about the development of CAR T-cell therapies in lymphoid malignancies

video

Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies

Dr. Hagemeister on the safety of CAR T-cell therapies for lymphoma patients and recommendations for managing toxicities associated with these ...

Related Videos

video-image

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

video-image

Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma

video-image

Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma

video-image

Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL

video-image

Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)

video-image

Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017

video-image

Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma

video-image

John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL

video-image

Fredrick B. Hagemeister, MD, on the exploration of CAR T-cell therapies in various lymphoma types

video-image

Fredrick B. Hagemeister, MD, describes how PD-1 inhibitors are being incorporated into FL treatment

video-image

Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies

video-image

Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies

video-image

John Burke, MD, lists the top findings from ASH 2017 regarding lymphoid malignancies

video-image

John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma

video-image

Martin Hutchings, MD, details the role of PET in the management of Hodgkin’s lymphoma

video-image

Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changing

video-image

David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies

video-image

David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study

video-image

Jane N. Winter, MD, discusses how CAR T-Cell therapies will impact the treatment of lymphomas

video-image

Jane N. Winter, MD, shares the clinical evidence supporting brentuximab vedotin in older patients

video-image

Jane N. Winter, MD, on whether checkpoint inhibitors can be used effectively in Hodgkin’s Lymphoma

video-image

Jane N. Winter, MD, explains how PD-1 and PD-L1 expression changes the way DLBCL is treated

video-image

Andre Goy, MD, tells us about the long-term outcomes of the ZUMA-1 trial

video-image

Andre Goy, MD tells us about the BTK combination with lenalidomide in MCL

video-image

Andre Goy, MD, discusses the best strategy for using ibrutinib in MCL

video-image

John Gerecitano, MD, discusses the medical unmet needs in the treatment of follicular lymphoma

video-image

John Gerecitano, MD, on what genetic predictors of response we have for follicular lymphoma

video-image

John Gerecitano, MD, discusses how PET staging affects outcomes and prognosis of follicular lymphoma

video-image

John Gerecitano, MD, on predictors of response to tazemetostat in diffuse large B-cell lymphoma

video-image

Miles Prince, MD, discusses I-O compounds and T-Cell Lymphoma treatment algorithms

video-image

Miles Prince, MD, on which emerging compounds for T-Cell Lymphomas look promising

video-image

Miles Prince, MD, discusses the efficacy and safety of brentuximab vedotin to treat CTCL patients

video-image

Miles Prince, MD, on the role CD30 plays when selecting a treatment algorithm for CTCL patients

video-image

Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients

video-image

Sattva Neelapu, MD, on novel agents and up-front approaches showing efficacy in lymphomas

video-image

Sattva Neelapu, MD, discusses efficacy results of the ZUMA-1 trial

video-image

John P. Leonard, MD, on CAR-T cell therapies being developed for the treatment of lymphomas

video-image

John P. Leonard, MD, on the role checkpoint inhibitors play in lymphoma treatment algorithms

video-image

John P. Leonard, MD, discusses novel agents for treating aggressive lymphomas

video-image

Bruce D. Cheson, MD, on the role of nivolumab in Hodgkin Lymphoma

video-image

Sattva Neelapu, MD shares safety results of the ZUMA-1 trial in patients with NHL

video-image

Matthew Davids, MD discusses his study using ibrutinib plus FCR in younger CLL patients

video-image

John P. Leonard, MD discusses improving outcomes in high risk follicular lymphoma patients

video-image

Jeff Sharman, MD, offers perspective on CAR T-cell therapies for the treatment of NHL

video-image

Kathryn Kolibaba, MD, lists key takeaways from the lymphoma oral session at ASCO 2017

video-image

Kathryn Kolibaba, MD, shares the results of the MAGNIFY study presented at ASCO

video-image

Kathryn Kolibaba, MD, describes the results of the BRIGHT study in front-line indolent NHL patients

video-image

Charles Saunders, MD, on the operational changes necessary to succeed in a value-based environment

video-image

Charles Saunders, MD, considers EHR providers in an era of value-based care

video-image

Charles Saunders, MD, discusses how value-based care is driving technology innovation in oncology

video-image

Maddy Herzfeld, discusses the challenges practices are facing when implementing patient engagement

video-image

Maddy Herzfeld, on solutions available for practices to implement better patient engagement

video-image

Maddy Herzfeld, on how oncology practices consume patient-reported data to improve patient care

video-image

Marcus Neubauer, MD, explains how clinical pathways save money when treating cancer

video-image

Marcus Neubauer, MD, discusses if clinical pathways create value in cancer care

video-image

Marcus Neubauer, MD, explains how clinical pathways differ from clinical guidelines

video-image

Marcus Neubauer, MD, discusses how practices and administrators can build higher pathway compliance

video-image

Mike Kolodziej, MD, explains the impact of the ACA on the insurance industry

video-image

Mike Kolodziej, MD, talks about how CMMI is changing the health care system

video-image

Mike Kolodziej, MD, discusses how technology is helping reform the way practices operate

video-image

Mike Kolodziej, MD, on how the clinical data set at Flatiron helps oncologists

video-image

Mike Kolodziej, MD, explains how Flatiron analytics help practices succeed in value based care

video-image

Jonathan Hirsch, President and Founder, Syapse, on the value of sharing patient-specific information

video-image

Jonathan Hirsch, discusses how precision medicine is being used to help improve cancer treatment

video-image

Jonathan Hirsch, on precision medicine software helping oncologists make therapeutic decisions

video-image

Ira Klein, MD, on what the shift toward oral oncolytics means for the supply chain

video-image

Ed Bassin, Ph.D., on what oncologists should be thinking about as they approach value based care

video-image

Ed Bassin, Ph.D., on working with hospital-based cancer centers vs community practices

video-image

Ed Bassin, Ph.D., explains the challenges for oncologists and practices with the OCM model

video-image

Ira Klein, MD, explains how risk management changes the way we manage supply chain

video-image

Ira Klein, MD, discusses how limited distribution impacts the delivery of oral cancer agents

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data is being used

video-image

Diana Verrilli, McKesson Specialty Health, on how claims data can be used in the OCM model

video-image

Steve D’Amato, R.Ph., talks about data capture and data analytics at New England Cancer Specialists

video-image

Steve D’Amato, R.Ph., talks about what technology his practice adopted to participate in OCM

video-image

Steve D’Amato, R.Ph., on why this is a challenging time for oncology practices

video-image

Steve D’Amato, R.Ph., explains how his practice helps patients get access to cancer care

video-image

Steve D’Amato, R.Ph., on whether the ACA changed access to care at New England Cancer Specialists

video-image

Jeffrey Scott, MD, shares the highest-impact areas of focus for value-based care savings

video-image

Jeffrey Scott, MD, on how important the drug channel is compared to reduction in hospitalizations

video-image

Jeffrey Scott, MD, discusses best practices for a GPO to help with value-based savings

video-image

Jeffrey Scott, MD, explains his vision for how GPOs must evolve in the era of value-based care

video-image

Bobby Green, MD, on using genomic data to prescreen eligibility for clinical trials

video-image

Bobby Green, MD, discusses collaboration efforts between Flatiron and Foundation Medicine

video-image

Bobby Green, MD, on leveraging genomic testing into actionable data

video-image

Dave Terry, Chief Executive Officer, on the keys to success when participating in APMs

video-image

Dave Terry, Chief Executive Officer, shares his thoughts on Alternative Payment Models of the future

video-image

Dave Terry, Chief Executive Officer, explains why practices should participate in APMs

video-image

James Hamrick, MD, shares his thoughts on how we are evolving toward a learning health care system

video-image

Debra Patt, MD, on what tele-health brings to cancer care

video-image

Debra Patt, MD, explains how data systems help with patient care delivery in community oncology

video-image

Linda Bosserman, MD, explains what MACRA means for oncologists today

video-image

Linda Bosserman, MD, discusses the highlights of the MACRA panel at CCBS 2017

video-image

Lili Brillstein, M.P.H., explains the primary goal of an episode of care

video-image

Lili Brillstein, M.P.H., explains how an episode of care is different from a bundled payment

video-image

Harlan Levine, MD, tells us about the continuous cycle of learning and improving at City of Hope

video-image

Harlan Levine, MD, on the philosophy for establishing quality metrics as they relate to an ACO

video-image

James Hamrick, MD, on using real world evidence to learn how to treat cancer patients

video-image

Lili Brillstein, M.P.H., shares her thoughts on the keys to success to make episodes of care work

video-image

Lili Brillstein, M.P.H., explains the requirements that must be met in an episode assessment

video-image

Harlan Levine, MD, on treating patients in this era of high cost cancer drugs

video-image

Harlan Levine, MD, on how cancer care navigators impact quality of care at City of Hope

video-image

James Hamrick, MD, explains how EMRs help connect patients and caregivers

video-image

Debra Patt, MD, explains how decision support tools improve the quality and delivery of cancer care

video-image

Debra Patt, MD, explains using predictive analytics to improve cancer care delivery

video-image

Linda Bosserman, MD, explains “Pick Your Pace” as it relates to participation in MACRA

video-image

Linda Bosserman, MD, on deciding whether to participate in MIPS or AAPM

video-image

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

video-image

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

video-image

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

video-image

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

video-image

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

video-image

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

video-image

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

video-image

Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)

video-image

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

video-image

James R. Downing, MD, explains the mission of St. Jude Children’s Research Hospital

video-image

Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients

video-image

Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients

video-image

Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations

video-image

Andrew Lane, MD, PhD, shares outcomes from the phase 2 study of SL-401 in patients with BPDCN

video-image

Jesus San-Miguel, MD, on daratumumab in a first-line setting as a result of the ALCYON study

video-image

Jesus San-Miguel, MD, explains the efficacy and safety outcomes of the ALCYON clinical study

video-image

Jens G. Lohr, MD, PhD, discusses the kind of information we can gather from liquid biopsy

video-image

Jens G. Lohr, MD, PhD, on utilizing liquid biopsy and how it compares to bone marrow biopsy

video-image

James Essell, MD, discusses the concerns for patients receiving allogeneic transplantations

video-image

James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy

video-image

Jorge Cortes, MD, on how generic imatinib is being adopted as an alternative to branded imatinib

video-image

Jorge Cortes, MD, on what was discussed at ASH 2017 regarding treatment discontinuation in AML

video-image

Edward A. Copelan, MD, shares highlights from ASH 2017 regarding treatment of acute myeloid leukemia

video-image

Edward A. Copelan, MD, considers whether azacitidine can be used for induction in AML

video-image

James R. Downing, MD, discusses the significant studies presented at ASH 2017

video-image

James R. Downing, MD, on the evolution of St. Jude Children’s Research Hospital

video-image

Keith Pratz, MD, on the proportion of AML patients who fall into the frail category

video-image

Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients

video-image

Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients

video-image

Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients

video-image

Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients

video-image

Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML

video-image

Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML

video-image

Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions

video-image

Habte Yimer, MD, on daratumumab, cyclophosphamide, bortezomib, & dexamethasone in relapsed MM

video-image

Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients

video-image

Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017

video-image

Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients

video-image

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment

video-image

Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy

video-image

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

video-image

Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses

video-image

Parameswaran Hari, MD, MRCP, MS, considers the remaining unmet medical needs in MM

video-image

Parameswaran Hari, MD, MRCP, MS, discusses the clinical relevance of minimal residual disease

video-image

Parameswaran Hari, MD, MRCP, MS, provides an update on how MM patients are staged at diagnosis

video-image

Parameswaran Hari, MD, MRCP, MS, on promising cellular immunotherapy studies from ASH 2017

video-image

Parameswaran Hari, MD, MRCP, MS, on how the field of immunotherapy is evolving for MM patients

video-image

Parameswaran Hari, MD, MRCP, MS, on checkpoint inhibitors and MM treatment algorithms

video-image

David Miklos, MD, PhD, explains how ibrutinib is being studied for the treatment of GVHD

video-image

David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD

video-image

Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients

video-image

Michael Boxer, MD, considers broader uses for fostamatinib

video-image

Paul Richardson, MD, on the importance of real world evidence (RWE)

video-image

Paul Richardson, MD, shares the efficacy outcomes of GSK-916 in relapsed/refractory MM patients

video-image

Paul Richardson, MD, on adding CAR T-cell therapy to multiple myeloma treatment algorithms

video-image

Robert Soiffer, MD, on other applications that IL-2 might have outside of treating chronic GVHD

video-image

Robert Soiffer, MD, on some of the innovative approaches to treating chronic GVHD

video-image

Robert Soiffer, MD, discusses current treatments available for chronic GVHD

video-image

Robert Soiffer, MD, explains GVHD and some of the complications that come along with it

video-image

Robert M. Rifkin, MD, on excluding transplantation from MM treatment algorithms

video-image

Robert M. Rifkin, MD, discusses if COMPASS is close to its goal of achieving whole genome sequencing

video-image

Robert M. Rifkin, MD, on the Connect Multiple Myeloma patient registry improving characterization

video-image

Robert M. Rifkin, MD, on how the Connect Multiple Myeloma patient registry is helping patients

video-image

David S. Siegel, MD, shares his thoughts on the most exciting clinical trial presented at ASH 2017

video-image

David S. Siegel, MD, discusses proteasome inhibitors and Multiple Myeloma

video-image

David S. Siegel, MD, discusses how stem cell transplant figures into MM treatment algorithms

video-image

David S. Siegel, MD, on how molecular profiling is helping drive treatment strategies

video-image

C. Ola Landgren, MD, discusses remaining major unmet medical needs for MM

video-image

C. Ola Landgren, MD, discusses risk factors for developing AML or MDS after treatment of MM

video-image

C. Ola Landgren, MD, discusses continuous therapy vs fixed duration therapy in MM patients

video-image

C. Ola Landgren, MD, on MRD as a legitimate surrogate endpoint in multiple myeloma clinical trials

video-image

John Gerecitano, MD, talks about tazemetostat’s class and mechanism of action

video-image

Miles Prince, MD, on the challenges to recruit and accrue patients to rare-cancer clinical studies

video-image

Sattva Neelapu, MD, shares his approach to optimizing CAR T-Cell therapies

video-image

John P. Leonard, MD, on the role social media plays in medicine

video-image

Gary Gordon, MD, PhD, on MRD endpoint for outcomes in the MURANO study

video-image

Gary Gordon, MD, PhD, discusses safety concerns in the phase 3 MURANO clinical trial

video-image

Gary Gordon, MD, PhD, discusses efficacy results of the phase 3 MURANO clinical trial

video-image

Matthew Davids, MD, on how checkpoint inhibitors are being developed for hematologic malignancies

video-image

Sagar Lonial MD, FACP, on expectations for response in the challenging patient type

video-image

Sagar Lonial MD, FACP, on MM patients not responding to monotherapy and combination regimens

video-image

Sagar Lonial MD, FACP, discusses unmet need for multiple myeloma patients

video-image

Sagar Lonial MD, FACP, on predicting venetoclax sensitivity in MM using biologic active assays

video-image

Bruce D. Cheson, MD, discusses care, toxicities, and outcomes treating CLL patients with venetoclax

video-image

Bruce D. Cheson, MD on choosing a front-line therapeutic regimen for CLL patients

video-image

Sattva Neelapu, MD shares his advice for sites that are new to treating with CAR T-Cell therapies

video-image

Matthew Davids, MD discusses how he typically treats front line CLL outside of a clinical study

video-image

Sagar Lonial MD, FACP tells us about the immunomodulatory mechanism of action of daratumumab

video-image

Sagar Lonial MD, FACP on whether relapsed multiple myeloma patients should be profiled molecularly

video-image

Bruce D. Cheson, MD discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL

video-image

John P. Leonard, MD discusses lenalidomide plus rituximab for the treatment of MCL